Scientists identify DNA signature linked to prostate cancer severity

Findings published in renowned journal Nature



January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment. 


“We hope that this research mode of testing will now go into the clinical mode in the next two to five years, and really change clinical practice for men with prostate cancer in Canada and worldwide,” said Dr. Bristow.

“This work really gives us a map to what is going on inside a prostate cancer cell, and will become the scaffold on which precision therapy will be built,” said Dr. Boutros.

“I applaud the researchers and everyone involved in making this possible,” said Reza Moridi, Ontario Minister of Research, Innovation and Science. “Collaborations like this are key to driving scientific discoveries and ultimately delivering better care for prostate cancer patients.”

Through funding of approximately $20 million, research of this magnitude has been made possible through a partnership between the Movember Foundation, Prostate Cancer Canada, and the Ontario Institute for Cancer Research, who have released the following joint statement:

“From the tireless work of researchers to the selfless giving of donors, we applaud the efforts of everyone who has played a role in helping make CPC-GENE possible. Since its beginnings as an ambitious undertaking that was massive in scope, the goal of this project has been to greatly improve personalized care for men with prostate cancer. The findings published in Nature represent a monumental stride towards that goal. Together, we will continue to advance this important work on behalf of the one in seven Canadian men who will be diagnosed with prostate cancer and their families.”

Full Article: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature20788.html
-30-

For more information please contact:
Adam Miller
Manager, Communications
Prostate Cancer Canada
416 441 2131 ext. 235
adam.miller@prostatecancer.ca



Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More

Plaid for Dad participation skyrockets in third year

July 7, 2017 - TORONTO, ON - Launched for the first time in 2015, Prostate Cancer Canada's (PCC) Plaid for Dad campaign has further established itself as the way Canadians are choosing to give back on Father's Day weekend.
More


Click here for news archive